SAN DIEGO & SOUTH SAN FRANCISCO--(BUSINESS WIRE)--
ResMed (NYSE: RMD, ASX: RMD), a global leader in sleep apnea treatment
and connected health solutions, and Verily, an Alphabet company, today
announced their agreement to form a new joint venture.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180711005254/en/
Combining ResMed’s expertise in sleep apnea and Verily’s advanced health
data analytics technologies, the U.S.-based joint venture will study the
health and financial impacts of undiagnosed and untreated sleep apnea,
and develop software solutions that enable healthcare providers to more
efficiently identify, diagnose, treat and manage individuals with sleep
apnea and other breathing related sleep disorders.
Sleep apnea is a sleep breathing disorder that affects an estimated 54
million Americans (calculated based on a 16-country prevalence data
study),1 and is associated with heart disease, stroke, type 2
diabetes and other life-threatening conditions. Despite the condition’s
high prevalence and increasing public awareness, past research has shown
that approximately 80 percent of individuals with obstructive sleep
apnea are undiagnosed, 2 untreated and therefore unaware of
their own risk and of the benefits that therapy could provide.
“The vast majority of people with sleep apnea don’t realize they have
it, and therefore don’t seek accessible, effective treatment to mitigate
its effects and long-term health risks,” said ResMed Chief Medical
Officer Carlos M. Nunez, M.D. “The combined industry expertise, scalable
infrastructure, and data analytics capabilities of ResMed and Verily can
unlock meaningful ways to identify these individuals and support their
journey to improved sleep, health and quality of life.”
“Approaching a widespread health problem like sleep apnea through
collecting, organizing and activating health data is central to Verily’s
mission,” said Jessica Mega, M.D., M.P.H., Chief Medical and Scientific
Officer at Verily. "By better identifying at-risk individuals as well as
generating real-world evidence regarding the value and effectiveness of
treatment, this collaboration has the potential to improve outcomes for
millions of people living with sleep apnea, and potentially other
related conditions."
The joint venture, subject to customary closing conditions, including
regulatory approvals, will operate as a separate venture from ResMed and
Verily.
About ResMed
ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health company
with more than 5 million cloud-connected devices for daily remote
patient monitoring, changes lives with every breath. Its award-winning
devices and software solutions help treat and manage sleep apnea,
chronic obstructive pulmonary disease and other respiratory conditions.
Its 6,000-member team strives to improve patients’ quality of life,
reduce the impact of chronic disease and save healthcare costs in more
than 120 countries. ResMed.com
About Verily
Launched in 2015, Verily is a subsidiary of Alphabet focused on life
sciences and healthcare. Verily’s mission is to make the world’s health
data useful so that people enjoy healthier lives. Verily develops tools
and devices to collect, organize and activate health data, and creates
interventions to prevent and manage disease. Verily partners with
leading life sciences, medical device and government organizations,
using deep hardware, software, scientific, and healthcare expertise to
enable faster development, meaningful advances, and deployment at scale.
For more information, please visit www.verily.com
-
Benjafield A et al. Am J Resp Crit Care Med 2018. Abstract
presented at ATS 2018: https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A3962#aff3
(full publication pending); Peppard PE et al. Am J Epidemiol 2013:
https://www.ncbi.nlm.nih.gov/pubmed/23589584
-
https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180711005254/en/
ResMed
For media:
Jayme Rubenstein, +1 858-836-6798
news@resmed.com
or
For
investors:
Amy Wakeham, +1 858-836-5000
investorrelations@resmed.com
or
Verily
For
media and investors:
Carolyn Wang, 415-736-2437
press@verily.com
Source: ResMed